New perspectives on the neurodevelopmental effects of SSRIs

Trends Pharmacol Sci. 2010 Feb;31(2):60-5. doi: 10.1016/j.tips.2009.11.003. Epub 2009 Dec 4.

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for the treatment of depression and anxiety-related disorders. These drugs target the serotonin transporter (5-HTT) and increase serotonin signalling. Although chronic SSRI administration has few reported side effects, recent observations suggest that it could have long-term effects on neurodevelopment. First, 5-HTT is transiently expressed in many brain areas during development. Second, 5-HTT blockade during development causes wiring defects in these areas. These effects are seen most clearly in the sensory systems. Third, the behavioural effects of 5-HTT blockade during development are sometimes dramatically different from the effects of 5-HTT blockade during adulthood. Most of this evidence was collected from studies with 5-HTT knockout mice and rats. However, the phenotypes associated with low or high functioning 5-HTT alleles in humans can result from similar developmental alterations in 5-HT levels. Here, we review the existing evidence on the long-term effects of developmental SSRI exposure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Behavior, Animal / drug effects
  • Brain / drug effects*
  • Female
  • Fetus / drug effects*
  • Humans
  • Mice
  • Pregnancy
  • Promoter Regions, Genetic
  • Rats
  • Selective Serotonin Reuptake Inhibitors / adverse effects*
  • Serotonin Plasma Membrane Transport Proteins / genetics
  • Signal Transduction / drug effects

Substances

  • Serotonin Plasma Membrane Transport Proteins
  • Serotonin Uptake Inhibitors